Companies · BNTX
BioNTech
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 3, 2026
BioNTech Q3 2026: Revenue guidance raised at midpoint; pumitamig+ADC enters first global Phase 3 as oncology pipeline accelerates toward 2030 multi-product ambition
BioNTech raised the midpoint of its full-year 2026 revenue guidance to €1.7–1.9 billion following Q3 2026 revenues of €1,289.2 million, while year-to-date revenues declined versus the prior year period driven by lower COVID-19 vaccine demand. The most strategically significant development this quarter is the initiation of the first global Phase 3 trial of pumitamig in combination with an ADC (sacituzumab govitecan, in collaboration with Gilead), marking the pipeline's transition from proof-of-concept to registrational execution across multiple tumor types. BioNTech simultaneously reported that trastuzumab pamirtecan met its primary PFS endpoint in HR+/HER2-low metastatic breast cancer but with only modest improvement, introducing a near-term pipeline setback that has deferred BLA submission planning to active discussion.
Tone: mixedRevenue
€2.9B
BNTX 20-F · FY 2025 · EUR
Revenue FY2024
€2.8B
Founded
2008
Headquarters
Mainz, Germany
Profile
BNTX 20-F Item 4.B · Mar 10, 2026BioNTech SE is a global next-generation immunotherapy company focused on developing novel medicines against cancer, infectious diseases, and other serious conditions. The company combines mRNA technology, protein-based therapeutics including antibody-drug conjugates, and cell therapy platforms with integrated GMP manufacturing and AI-driven computational medicine capabilities. Its sole marketed product is Comirnaty, the first-ever approved mRNA vaccine, developed in partnership with Pfizer.
Read filing description ↓ Collapse description ↑
We are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, or AI, and machine learning, or ML, capabilities to discover, develop and commercialize our marketed product and product candidates. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes investigational messenger ribonucleic acid, or mRNA immunotherapies and protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates, or ADCs). Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. In infectious diseases, our goal is to develop vaccines and therapeutics caused by respiratory viruses, latent viruses, bacteria and parasites. Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed pharmaceutical product, Comirnaty.
Primary products
- Comirnaty (BNT162b2) – COVID-19 mRNA vaccine
- Pumitamig (BNT327/BMS986545) – bispecific immunomodulator targeting PD-L1 and VEGF-A
- Autogene cevumeran (RO7198457/BNT122) – individualized neoantigen specific immunotherapy (iNeST)
- Trastuzumab pamirtecan (BNT323/DB-1303) – HER2-directed ADC
- BNT324/DB-1311 – B7H3-directed ADC
- BNT325/DB-1305 – TROP2-directed ADC
End markets
Geographies
Named customers
Named competitors
“We maintained our leadership position in the global COVID-19 vaccine market, achieving a market share of over 50% during the fall 2025 vaccination season.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Reported in EUR. Total revenues increased from €2,751.1 million in 2024 to €2,869.9 million in 2025, driven by €613.0 million in revenues from out-licensing related to the BMS pumitamig collaboration, partially offset by an €436.8 million decline in COVID-19 vaccine revenues.
The rest of BNTX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.